Article Text

PDF
AB1117 Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases under treatment with anti-tumor necrosis factor drugs
  1. ALB Morsch1,
  2. G Garziera2,
  3. F Otesbelgue3,
  4. FL Staub3,
  5. PE Palominos1,
  6. CV Brenol1,3,
  7. DR Silva2,3,4
  1. 1Serviço de Reumatologia
  2. 2Programa de Pόs-Graduação em Ciências Pneumolόgicas, Hospital de Clínicas de Porto Alegre
  3. 3Faculdade de Medicina, Universidade Federal do Rio Grande do Sul
  4. 4Serviço de Pneumologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

Abstract

Background The introduction of biological agents, especially the tumor necrosis factor inhibitors (anti-TNF) for the treatment of rheumatic diseases increased the risk of developing tuberculosis (TB). Screening for latent TB infection (LTBI) is strongly recommended before starting therapy with anti-TNF agents.

Objectives This study aimed to identify the prevalence of LTBI and TB among patients with rheumatic diseases on anti-TNF drugs.

Methods In a cross-sectional study, the electronic medical records of all adult patients (≥18 years old) undergoing anti-TNF treatment at Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, were reviewed. Every patient underwent Tuberculin Skin Test (TST) before starting anti-TNF treatment.

Results In total, 176 patients were included. The mean age was 51.9±12.4 years, 34.7% were males, and 90.9% were white. The underlying diseases were rheumatoid arthritis (RA) in 50.6% (N=89), ankylosing spondylitis (AS) in 27.8% (N=49) and psoriatic arthritis (PsA) in 17.6% (N=31). Anti-TNF agents started after TST were: infliximab (22.7%, N=40), adalimumab (48.9%, N=86), etanercept (27.3%, N=48), and golimumab (1.1%, N=2). The prevalence of positive TST was 29.5%. Household contact with TB was significantly associated with a positive TST (p=0.020). RA patients had lower TST reactions than AS patients (p=0.022). There were six cases of TB (3.4%) diagnosed during anti-TNF therapy.

Conclusions We demonstrated a high prevalence of positive TST (29.5%) among patients with rheumatic diseases in a region with high TB prevalence. Our data corroborates the ACR's recommendation that patients who live in high TB incidence settings should be tested annually for LTBI.

References

  1. Ishiguro T, Takayanagi N, Kagiyama N, Yanagisawa T, Sugita Y: Characteristics of tuberculosis in patients with rheumatoid arthritis: a retrospective single-center study. Intern Med 2014, 53: 1291–1298.

  2. Arkema EV, Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Askling J: Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? Ann Rheum Dis 2015, 74: 1212–1217.

  3. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM et al.: 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken ) 2012, 64: 625–639.

References

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.